Health & Wellness

So, Is Everyone Changing Their Minds About GLP-1s Now?

July 27, 2025

The wellness landscape is constantly evolving, but few topics have gained as much traction in the mainstream as GLP-1s. Just a few years ago, most people only encountered these injectable medications during a doctor’s visit for type 2 diabetes. Now they headline TikTok feeds, dinner table debates, and corporate earnings calls in equal measure.

On Real Pod, host Victoria Garrick Browne dives into what she calls a “chaotic life update,” admitting, “I wanna revisit the Ozempic conversation because I’ve had some changes of heart, if you will.” Her personal evolution from frustration to acceptance mirrors a broader cultural reckoning: While the allure of smaller dress sizes may have sparked the craze, the real story involves access, mental health, and society’s evolving standards of beauty.

For women juggling careers, friendships, and a never-ending scroll, it’s no longer enough to ask whether GLP-1s lead to weight loss. The better question is what they mean for holistic wellness and how we support each other as the narrative continues to evolve.

Why everyone suddenly talks about GLP-1s

Early in the podcast, Garrick Browne marvels at the transformation, “It’s so crazy to even think about how a few years ago, we had never heard that word. Like, it didn’t exist. And now it’s like GLP-1s feel so mainstream.” The timeline has been remarkably compressed: Ozempic gained FDA approval for diabetes in December 2017 and became a household name by 2022, when off-label weight loss use exploded. Weekly injections have become cocktail party fodder, and digital ads now promise “no more injections” thanks to FDA-approved oral formulations sold under the name Rybelsus, with more in development from Eli Lilly and Pfizer.

Studies continue to link GLP-1s to reduced cardiovascular risk and even potential benefits for conditions such as fatty liver disease. Food brands are developing protein-packed, portion-controlled lines tailored to users with smaller appetites, while shortages prompt some patients to turn to unregulated compounded versions.

An emotional evolution: from frustration to acceptance

When GLP-1s first took off, Garrick Browne admits she felt blindsided. “I was for sure triggered and projecting from a place of myself that was angry and felt like this wasn’t fair,” she confesses, tracing her reaction to years spent healing from disordered eating. Watching celebrities unveil fast transformations revived old insecurities she thought she had already put to rest.

Through therapy and self-reflection, her outlook changed. “I think in the beginning, I had way more anger and animosity towards this conversation than I do now because I’ve been able to process it and accept it more and become desensitized to it because it’s everywhere,” she notes. This shift resonates with anyone who has done the hard work of body acceptance, only to see society move the goalposts yet again.

Crucially, Garrick Browne distinguishes between medical necessity and pure aesthetics. “I wanna completely exclude from this conversation people who have had health conditions that this has miraculously helped,” she points out. “I’m purely talking about people who use the drug for purely aesthetic reasons.”

Beyond weight: equity, side effects, and social dynamics

The chatter might center on shedding pounds, but the real stakes stretch far wider, as the American Psychological Association correctly points out. At roughly $1,000 a month, GLP‑1s remain out of reach for many without robust insurance, creating what critics call “thin privilege by prescription.” Shortages only intensify the divide; diabetes patients sometimes struggle to refill vital medication while wellness seekers hunt for quick routes to a smaller waist.

Side effects also complicate the picture. Users often report nausea, vomiting, and constipation in the early weeks, and there is growing awareness of more serious, though rare, risks like pancreatitis and gall bladder disorders. Another wrinkle emerges when treatment stops: Rapid weight regain can follow, revealing that GLP-1s work best in tandem with long-term lifestyle changes, rather than as a standalone magic.

Even restaurants and grocery chains are feeling the ripple. Menu developers now consider half-size entrées to suit smaller appetites. At the same time, snack brands are developing nutrient-dense mini-meals designed to promote satiety. Meanwhile, ethicists debate whether drug manufacturers should prioritize cardiovascular and diabetic indications before marketing to weight-loss consumers.

A path toward wiser conversation

Garrick Browne refuses to dismiss anyone’s feelings about this cultural moment. “Two things can be true at the same time,” she reminds listeners. When comparison creeps in, she offers a shared mantra: “I’m going through it with you.”

Instead of obsessing over before-and-after photos, we can demand transparent pricing, improved insurance coverage, and honest discussion of side effects. We can acknowledge the mental health hurdles that often accompany weight-centric goals, ensuring that therapy and nutrition counseling remain part of the plan. And we can cheer scientific breakthroughs while still challenging social norms that equate thinness with worthiness.

GLP-1s have permanently altered the wellness landscape, but the conversation has matured past the scale. It now embraces questions of equity, holistic health, and regulatory ethics. Garrick Browne’s willingness to share her journey—from anger to empathy—illustrates how confronting our own biases can create space for more inclusive and compassionate dialogue.